MedTrace Logo

Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

NCT00544700 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2020-02-20

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab as maintenance therapy is more effective than observation in treating patients with colorectal cancer.

PURPOSE: This randomized phase III trial is studying bevacizumab to see how well it works in treating patients who have undergone first-line therapy for metastatic colorectal cancer.

Conditions

Interventions

BIOLOGICAL

bevacizumab

7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity

OTHER

no maintenance

No treatment until progression

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Dieter Koeberle, MD · St. Claraspital Basel

  • Peter Moosmann, MD · Kantonsspital Aarau

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-26
Primary Completion
2013-01-21
Completion
2019-12-12

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00544700 on ClinicalTrials.gov